×
To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.
Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.
As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.
DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.
The general agreement for patients whose AP is the form of presentation of CML is to go on with the TKI indefinitely if they achieve a good response, as it is the case with this patient. Given the patient’s high risk because of his CML phase, TKI discontinuation is not recommended, and treatment should be given indefinitely. One possibility would be to reduce dasatinib dose to 100 mg daily, taking into account the sustained good molecular response.
ORIGINAL CASE:
20 year old male
diagnosed as CML in AP in January 2017
no comorbidities
Started on Dasatinib 140 mg /day
His RQ-PCR is 0 % since last 2 years
Is he a candidate for TRF ? If yes when ?
This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.View our Privacy Policy